Compile Data Set for Download or QSAR

Found 128 hits of affinity data for UniProtKB/TrEMBL: P01275   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Pro-glucagon (Homo sapiens (Human))	BDBM2437 (US8507533, 157) Show SMILES CC1(C)CC(C1)C(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C25H27F3N6O3/c1-24(2)9-17(10-24)21(15-3-5-16(6-4-15)22(37)29-8-7-20(35)36)33-19-12-30-23(31-13-19)34-14-18(11-32-34)25(26,27)28/h3-6,11-14,17,21,33H,7-10H2,1-2H3,(H,29,37)(H,35,36)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	5.55	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100827 (US8507533, 138 | US8507533, 151 | US8507533, 374) Show SMILES Cc1cc(OC(C2CCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F Show InChI InChI=1S/C27H28F3N3O4/c1-16-12-22(13-17(2)24(16)33-15-21(14-32-33)27(28,29)30)37-25(18-4-3-5-18)19-6-8-20(9-7-19)26(36)31-11-10-23(34)35/h6-9,12-15,18,25H,3-5,10-11H2,1-2H3,(H,31,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	5.75	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100806 (US8507533, 114 | US8507533, 115 | US8507533, 330) Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-20-7-8-21(31-14-20)34-15-19(13-32-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	7.60	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM2390 (US8507533, 146) Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)[C@@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1 Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)/t24-/m0/s1	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	9.05	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM142039 (US8927577, 118 | US8927577, 20 | US8927577, 35) Show SMILES Cc1cc2cc(F)ccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C27H30FN3O3/c1-16-12-19-13-21(28)8-9-22(19)30-25(16)31-24(20-14-27(2,3)15-20)17-4-6-18(7-5-17)26(34)29-11-10-23(32)33/h4-9,12-13,20,24H,10-11,14-15H2,1-3H3,(H,29,34)(H,30,31)(H,32,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	14	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100806 (US8507533, 114 | US8507533, 115 | US8507533, 330) Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-20-7-8-21(31-14-20)34-15-19(13-32-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	15.8	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100796 (US8507533, 101) Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1 Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	17	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100827 (US8507533, 138 | US8507533, 151 | US8507533, 374) Show SMILES Cc1cc(OC(C2CCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F Show InChI InChI=1S/C27H28F3N3O4/c1-16-12-22(13-17(2)24(16)33-15-21(14-32-33)27(28,29)30)37-25(18-4-3-5-18)19-6-8-20(9-7-19)26(36)31-11-10-23(34)35/h6-9,12-15,18,25H,3-5,10-11H2,1-2H3,(H,31,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	20.2	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM2376 (US8507533, 137) Show SMILES CCC[C@H](Nc1ccc(nc1)-n1cc(cn1)C(C)(C)C)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H33N5O3/c1-5-6-22(18-7-9-19(10-8-18)25(34)27-14-13-24(32)33)30-21-11-12-23(28-16-21)31-17-20(15-29-31)26(2,3)4/h7-12,15-17,22,30H,5-6,13-14H2,1-4H3,(H,27,34)(H,32,33)/t22-/m0/s1	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	20.2	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM142041 (US8927577, 22) Show SMILES CC1(C)CC(C1)C(Nc1cnc2cc(F)ccc2c1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H28FN3O3/c1-26(2)13-19(14-26)24(30-21-11-18-7-8-20(27)12-22(18)29-15-21)16-3-5-17(6-4-16)25(33)28-10-9-23(31)32/h3-8,11-12,15,19,24,30H,9-10,13-14H2,1-2H3,(H,28,33)(H,31,32)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	25	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100844 (US8507533, 160 | US8507533, 398) Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C28H29N5O3/c1-2-6-25(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-24-13-14-26(30-18-24)33-19-23(17-31-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,25,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	25.7	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM2391 (US8507533, 147) Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)[C@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1 Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)/t24-/m1/s1	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	26.7	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100850 (US8507533, 168) Show SMILES CC(C)C[C@@H](Nc1ccc(cn1)C(=O)NCCC(O)=O)c1cc(C)c(c(C)c1)-n1cc(cn1)C(F)(F)F Show InChI InChI=1S/C26H30F3N5O3/c1-15(2)9-21(33-22-6-5-18(12-31-22)25(37)30-8-7-23(35)36)19-10-16(3)24(17(4)11-19)34-14-20(13-32-34)26(27,28)29/h5-6,10-15,21H,7-9H2,1-4H3,(H,30,37)(H,31,33)(H,35,36)/t21-/m1/s1	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	27.4	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100852 (US8507533, 170 | US8507533, 419) Show SMILES Cc1cc(cc(C)c1-n1cc(cn1)C(F)(F)F)C(Nc1ccc(cn1)C(=O)NCCC(O)=O)C1CCCC1 Show InChI InChI=1S/C27H30F3N5O3/c1-16-11-20(12-17(2)25(16)35-15-21(14-33-35)27(28,29)30)24(18-5-3-4-6-18)34-22-8-7-19(13-32-22)26(38)31-10-9-23(36)37/h7-8,11-15,18,24H,3-6,9-10H2,1-2H3,(H,31,38)(H,32,34)(H,36,37)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	28	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100844 (US8507533, 160 | US8507533, 398) Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C28H29N5O3/c1-2-6-25(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-24-13-14-26(30-18-24)33-19-23(17-31-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,25,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	29	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100822 (US8507533, 129 | US8507533, 162 | US8507533, 399) Show SMILES CCCC(Nc1ccc(nc1)-n1cnc(c1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C28H29N5O3/c1-2-6-24(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-23-13-14-26(30-17-23)33-18-25(31-19-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,24,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	29.3	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM2241 (US8507533, 136) Show SMILES CCC[C@@H](Nc1ccc(nc1)-n1cc(cn1)C(C)(C)C)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H33N5O3/c1-5-6-22(18-7-9-19(10-8-18)25(34)27-14-13-24(32)33)30-21-11-12-23(28-16-21)31-17-20(15-29-31)26(2,3)4/h7-12,15-17,22,30H,5-6,13-14H2,1-4H3,(H,27,34)(H,32,33)/t22-/m1/s1	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	30.2	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100838 (US8507533, 153) Show SMILES CCCC(Oc1cc(C)c(c(OC)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H28F3N3O5/c1-4-5-21(17-6-8-18(9-7-17)25(35)30-11-10-23(33)34)37-20-12-16(2)24(22(13-20)36-3)32-15-19(14-31-32)26(27,28)29/h6-9,12-15,21H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	32.3	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM160576 (US9045389, 8) Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)-c1cc(Cl)ccc1CNc1ccc(cc1)-c1ccc(Cl)cc1Cl Show InChI InChI=1S/C29H23Cl3N2O3/c30-22-8-5-21(17-34-24-10-6-18(7-11-24)25-12-9-23(31)16-27(25)32)26(15-22)19-1-3-20(4-2-19)29(37)33-14-13-28(35)36/h1-12,15-16,34H,13-14,17H2,(H,33,37)(H,35,36)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	33	-39.7	n/a	n/a	n/a	n/a	n/a	7.4	4
Janssen Pharmaceutica NV US Patent					Assay Description Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und...				US Patent US9045389 (2015) BindingDB Entry DOI: 10.7270/Q2D21WC3
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM2240 (US8507533, 135) Show SMILES CC1(C)CC(C1)[C@H](Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-19-7-8-21(31-13-19)34-14-20(32-15-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)/t23-/m1/s1	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	35	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100837 (US8507533, 152) Show SMILES Cc1cc(OC(C2CC(C)(C)C2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F Show InChI InChI=1S/C29H32F3N3O4/c1-17-11-23(12-18(2)25(17)35-16-22(15-34-35)29(30,31)32)39-26(21-13-28(3,4)14-21)19-5-7-20(8-6-19)27(38)33-10-9-24(36)37/h5-8,11-12,15-16,21,26H,9-10,13-14H2,1-4H3,(H,33,38)(H,36,37)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	35.2	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM160577 (US9045389, 9) Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)-c1ccccc1CNc1ccc(cc1)-c1ccc(F)c(c1)[N+]([O-])=O Show InChI InChI=1S/C29H24FN3O5/c30-26-14-11-22(17-27(26)33(37)38)19-9-12-24(13-10-19)32-18-23-3-1-2-4-25(23)20-5-7-21(8-6-20)29(36)31-16-15-28(34)35/h1-14,17,32H,15-16,18H2,(H,31,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem	US Patent	38	-39.4	n/a	n/a	n/a	n/a	n/a	7.4	4
Janssen Pharmaceutica NV US Patent					Assay Description Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und...				US Patent US9045389 (2015) BindingDB Entry DOI: 10.7270/Q2D21WC3
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100805 (US8507533, 113) Show SMILES CCCC(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C22H23F3N6O3/c1-2-3-18(14-4-6-15(7-5-14)20(34)26-9-8-19(32)33)30-17-11-27-21(28-12-17)31-13-16(10-29-31)22(23,24)25/h4-7,10-13,18,30H,2-3,8-9H2,1H3,(H,26,34)(H,32,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	38.2	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM142039 (US8927577, 118 | US8927577, 20 | US8927577, 35) Show SMILES Cc1cc2cc(F)ccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C27H30FN3O3/c1-16-12-19-13-21(28)8-9-22(19)30-25(16)31-24(20-14-27(2,3)15-20)17-4-6-18(7-5-17)26(34)29-11-10-23(32)33/h4-9,12-13,20,24H,10-11,14-15H2,1-3H3,(H,29,34)(H,30,31)(H,32,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	39	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM2438 (US8507533, 158) Show SMILES CCOC(=O)CCNC(=O)c1ccc(cc1)C(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)C1CC(C)(C)C1 Show InChI InChI=1S/C27H31F3N6O3/c1-4-39-22(37)9-10-31-24(38)18-7-5-17(6-8-18)23(19-11-26(2,3)12-19)35-21-14-32-25(33-15-21)36-16-20(13-34-36)27(28,29)30/h5-8,13-16,19,23,35H,4,9-12H2,1-3H3,(H,31,38)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	41	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100861 (US8507533, 188) Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-19-7-8-21(31-13-19)34-14-20(32-15-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid PDB UniChem Similars	US Patent	42.2	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100864 (US8507533, 193) Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1cnc(nc1)-n1cnc(c1)C(F)(F)F)C1CCCC1 Show InChI InChI=1S/C24H25F3N6O3/c25-24(26,27)19-13-33(14-31-19)23-29-11-18(12-30-23)32-21(15-3-1-2-4-15)16-5-7-17(8-6-16)22(36)28-10-9-20(34)35/h5-8,11-15,21,32H,1-4,9-10H2,(H,28,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem	US Patent	44.7	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM160575 (US9045389, 7) Show SMILES Cc1cc(ccc1-c1ccccc1CNc1ccc(cc1)-c1ccc(Cl)cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C30H27ClN2O3/c1-20-18-23(30(36)32-17-16-29(34)35)10-15-27(20)28-5-3-2-4-24(28)19-33-26-13-8-22(9-14-26)21-6-11-25(31)12-7-21/h2-15,18,33H,16-17,19H2,1H3,(H,32,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	45	-39.0	n/a	n/a	n/a	n/a	n/a	7.4	4
Janssen Pharmaceutica NV US Patent					Assay Description Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und...				US Patent US9045389 (2015) BindingDB Entry DOI: 10.7270/Q2D21WC3
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100815 (US8507533, 122) Show SMILES CC(C)(C)c1cn(cn1)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1 Show InChI InChI=1S/C28H35N5O3/c1-28(2,3)23-17-33(18-31-23)24-13-12-22(16-30-24)32-26(19-6-4-5-7-19)20-8-10-21(11-9-20)27(36)29-15-14-25(34)35/h8-13,16-19,26,32H,4-7,14-15H2,1-3H3,(H,29,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	45.7	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100822 (US8507533, 129 | US8507533, 162 | US8507533, 399) Show SMILES CCCC(Nc1ccc(nc1)-n1cnc(c1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C28H29N5O3/c1-2-6-24(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-23-13-14-26(30-17-23)33-18-25(31-19-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,24,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	47.3	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM2229 (US8507533, 187 | US8507533, 448) Show SMILES CCC[C@H](Oc1cc(C)c(c(C)c1)-n1cc2ccccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C29H31N3O4/c1-4-7-26(21-10-12-22(13-11-21)29(35)30-15-14-27(33)34)36-24-16-19(2)28(20(3)17-24)32-18-23-8-5-6-9-25(23)31-32/h5-6,8-13,16-18,26H,4,7,14-15H2,1-3H3,(H,30,35)(H,33,34)/t26-/m0/s1	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	47.8	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM142042 (US8927577, 23) Show SMILES CC1(C)CC(C1)C(Nc1cnc2ccc(F)cc2c1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H28FN3O3/c1-26(2)13-19(14-26)24(30-21-12-18-11-20(27)7-8-22(18)29-15-21)16-3-5-17(6-4-16)25(33)28-10-9-23(31)32/h3-8,11-12,15,19,24,30H,9-10,13-14H2,1-2H3,(H,28,33)(H,31,32)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	50	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100824 (US8507533, 131) Show SMILES Cc1cc(OC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cnc(c1)C(F)(F)F Show InChI InChI=1S/C28H30F3N3O4/c1-17-13-22(14-18(2)25(17)34-15-23(33-16-34)28(29,30)31)38-26(19-5-3-4-6-19)20-7-9-21(10-8-20)27(37)32-12-11-24(35)36/h7-10,13-16,19,26H,3-6,11-12H2,1-2H3,(H,32,37)(H,35,36)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	51	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM142038 (US8927577, 117 | US8927577, 19 | US8927577, 32) Show SMILES Cc1cc2ccccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C27H31N3O3/c1-17-14-20-6-4-5-7-22(20)29-25(17)30-24(21-15-27(2,3)16-21)18-8-10-19(11-9-18)26(33)28-13-12-23(31)32/h4-11,14,21,24H,12-13,15-16H2,1-3H3,(H,28,33)(H,29,30)(H,31,32)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	53	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100801 (US8507533, 109 | US8507533, 322) Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1F)C(=O)NCCC(O)=O Show InChI InChI=1S/C23H23F4N5O3/c1-2-3-19(17-6-4-14(10-18(17)24)22(35)28-9-8-21(33)34)31-16-5-7-20(29-12-16)32-13-15(11-30-32)23(25,26)27/h4-7,10-13,19,31H,2-3,8-9H2,1H3,(H,28,35)(H,33,34)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	57.2	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM2387 (US8507533, 143) Show SMILES CC(C)C[C@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cn1)C(=O)NCCC(O)=O Show InChI InChI=1S/C23H25F3N6O3/c1-14(2)9-19(18-5-3-15(10-28-18)22(35)27-8-7-21(33)34)31-17-4-6-20(29-12-17)32-13-16(11-30-32)23(24,25)26/h3-6,10-14,19,31H,7-9H2,1-2H3,(H,27,35)(H,33,34)/t19-/m0/s1	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	57.4	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100826 (US8507533, 133) Show SMILES CCCC(Oc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C28H28N4O4/c1-2-6-25(21-9-11-22(12-10-21)28(35)29-16-15-27(33)34)36-24-13-14-26(30-18-24)32-19-23(17-31-32)20-7-4-3-5-8-20/h3-5,7-14,17-19,25H,2,6,15-16H2,1H3,(H,29,35)(H,33,34)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	58	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM160583 (US9045389, 18) Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)-c1ccccc1CNc1ccc(cc1)-c1ccc(Cl)cc1 Show InChI InChI=1S/C29H25ClN2O3/c30-25-13-9-20(10-14-25)21-11-15-26(16-12-21)32-19-24-3-1-2-4-27(24)22-5-7-23(8-6-22)29(35)31-18-17-28(33)34/h1-16,32H,17-19H2,(H,31,35)(H,33,34)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	60	-38.3	n/a	n/a	n/a	n/a	n/a	7.4	4
Janssen Pharmaceutica NV US Patent					Assay Description Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und...				US Patent US9045389 (2015) BindingDB Entry DOI: 10.7270/Q2D21WC3
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100831 (US8507533, 144) Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(cn1)C1CC1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C28H33N3O4/c1-4-5-25(21-8-10-22(11-9-21)28(34)29-13-12-26(32)33)35-24-14-18(2)27(19(3)15-24)31-17-23(16-30-31)20-6-7-20/h8-11,14-17,20,25H,4-7,12-13H2,1-3H3,(H,29,34)(H,32,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	62.6	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100829 (US8507533, 140) Show SMILES CCCC(Oc1ccc(cc1)-n1cc2cc(Cl)ccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C27H26ClN3O4/c1-2-3-25(18-4-6-19(7-5-18)27(34)29-15-14-26(32)33)35-23-11-9-22(10-12-23)31-17-20-16-21(28)8-13-24(20)30-31/h4-13,16-17,25H,2-3,14-15H2,1H3,(H,29,34)(H,32,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	62.8	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100847 (US8507533, 163) Show SMILES Cc1nn(cc1Cl)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1 Show InChI InChI=1S/C25H28ClN5O3/c1-16-21(26)15-31(30-16)22-11-10-20(14-28-22)29-24(17-4-2-3-5-17)18-6-8-19(9-7-18)25(34)27-13-12-23(32)33/h6-11,14-15,17,24,29H,2-5,12-13H2,1H3,(H,27,34)(H,32,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem	US Patent	65.9	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100797 (US8507533, 105) Show SMILES CC(C)CC(Nc1cnc(c(C)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C25H28F3N5O3/c1-15(2)10-21(17-4-6-18(7-5-17)24(36)29-9-8-22(34)35)32-20-11-16(3)23(30-13-20)33-14-19(12-31-33)25(26,27)28/h4-7,11-15,21,32H,8-10H2,1-3H3,(H,29,36)(H,34,35)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	69.8	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100799 (US8507533, 107) Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(CC1CC1)Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F Show InChI InChI=1S/C24H24F3N5O3/c25-24(26,27)18-12-30-32(14-18)21-8-7-19(13-29-21)31-20(11-15-1-2-15)16-3-5-17(6-4-16)23(35)28-10-9-22(33)34/h3-8,12-15,20,31H,1-2,9-11H2,(H,28,35)(H,33,34)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	71.6	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM142038 (US8927577, 117 | US8927577, 19 | US8927577, 32) Show SMILES Cc1cc2ccccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C27H31N3O3/c1-17-14-20-6-4-5-7-22(20)29-25(17)30-24(21-15-27(2,3)16-21)18-8-10-19(11-9-18)26(33)28-13-12-23(31)32/h4-11,14,21,24H,12-13,15-16H2,1-3H3,(H,28,33)(H,29,30)(H,31,32)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	74	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM142030 (US8927577, 11 | US8927577, 30 | US8927577, 31) Show SMILES CC(C)CC(Nc1nc2ccccc2cc1C)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C25H29N3O3/c1-16(2)14-22(28-24-17(3)15-20-6-4-5-7-21(20)27-24)18-8-10-19(11-9-18)25(31)26-13-12-23(29)30/h4-11,15-16,22H,12-14H2,1-3H3,(H,26,31)(H,27,28)(H,29,30)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	76	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100856 (US8507533, 181) Show SMILES CC(C)(C)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C24H26F3N5O3/c1-23(2,3)21(15-4-6-16(7-5-15)22(35)28-11-10-20(33)34)31-17-8-9-19(29-12-17)32-13-18(30-14-32)24(25,26)27/h4-9,12-14,21,31H,10-11H2,1-3H3,(H,28,35)(H,33,34)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	87.2	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100816 (US8507533, 123) Show SMILES CC(C)c1cn(cn1)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1 Show InChI InChI=1S/C27H33N5O3/c1-18(2)23-16-32(17-30-23)24-12-11-22(15-29-24)31-26(19-5-3-4-6-19)20-7-9-21(10-8-20)27(35)28-14-13-25(33)34/h7-12,15-19,26,31H,3-6,13-14H2,1-2H3,(H,28,35)(H,33,34)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	88.4	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100830 (US8507533, 141) Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C26H28F3N3O4/c1-4-5-21(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-20-12-16(2)24(17(3)13-20)32-14-22(31-15-32)26(27,28)29/h6-9,12-15,21H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	89.5	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM142035 (US8927577, 16) Show SMILES CC(C)CC(Nc1ccc2cc(ccc2n1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C25H26F3N3O3/c1-15(2)13-21(16-3-5-17(6-4-16)24(34)29-12-11-23(32)33)31-22-10-7-18-14-19(25(26,27)28)8-9-20(18)30-22/h3-10,14-15,21H,11-13H2,1-2H3,(H,29,34)(H,30,31)(H,32,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	91	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair
Pro-glucagon (Homo sapiens (Human))	BDBM100798 (US8507533, 106) Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCC1 Show InChI InChI=1S/C24H24F3N5O3/c25-24(26,27)18-12-30-32(14-18)20-9-8-19(13-29-20)31-22(15-2-1-3-15)16-4-6-17(7-5-16)23(35)28-11-10-21(33)34/h4-9,12-15,22,31H,1-3,10-11H2,(H,28,35)(H,33,34)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar	PC cid PC sid UniChem Similars	US Patent	91.9	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.				US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 128 total )  |  Next  |  Last  >>

Jump to: